Drug Trial Radar · NCT05995704
Evaluation of Apraglutide on Gastric Emptying
Last checked: Nov 19, 2026Latest source record: Oct 24, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
42
Actual
Start
Mar 2, 2023
Primary completion
Jul 24, 2023
Study completion Jul 24, 2023
Sponsor
- Lead sponsor
- VectivBio AGIndustry
- Sponsor type
- Industry
- First posted
- Aug 16, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Other
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 45 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The primary objective is to assess the effect of apraglutide on gastric emptying of liquids in healthy subjects, as measured by the PK of acetaminophen mixed with a liquid meal.
Conditions
- Healthy Subjects
Interventions
ApraglutideDrug
Peptide analogue of GLP-2
PlaceboDrug
Matching placebo to apraglutide
AcetaminophenDrug
Acetaminophen mixed with a liquid meal
Primary outcomes
What the sponsor says the trial is designed to measure.
- Maximum plasma concentration (Cmax) of acetaminophenTime frame: 0-300 Minutes
- Time at which the maximum plasma concentration is observed (tmax) of acetaminophenTime frame: 0-300 Minutes
- Area under the acetaminophen concentration-time curve: AUCinf (AUClast in case AUCinf cannot be estimated)Time frame: 0-14 hours
- Area under the acetaminophen concentration-time curve: AUC0-300minTime frame: 0-300 Minutes
- Area under the acetaminophen concentration-time curve: AUC0-60minTime frame: 0-60 Minutes
Locations
1 site in 1 country. Site status is shown where the registry gives one.
ICON Clinical Research Unit
Groningen, Netherlands
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.